4Semana¡

Exelixis' blockbuster hope beats Bayer drug in pivotal cancer trial, sending shares higher

$EXEL (+0,22%)
$BAYN (+0,8%)

A combination with Exelixis' experimental drug zanzalintinib has beaten Bayer's gastrointestinal cancer drug Stivarga in a Phase 3 trial . The overall survival success brings Exelixis one step closer to its goal of developing the oral tyrosine kinase inhibitor into a product with annual sales of 5 billion dollars.


Exelixis is developing zanzalintinib as a successor to its lead oncology drug Cabometyx. By improving properties such as pharmacokinetic half-life, the company has developed a molecule that it believes could be approved for a range of diseases and significantly outperform Cabometyx's peak sales. The Phase 3 colorectal cancer trial was an important early test for zanzalintinib.


Researchers randomized 901 patients to receive Stivarga or zanzalintinib in combination with Roche's checkpoint inhibitor Tecentriq. Overall survival in previously treated metastatic colorectal cancer without microsatellite instability was significantly longer with the combination therapy than with Stivarga.


Analysts at William Blair said in a note to investors that meeting the study's co-primary endpoint represented a "significant commercial opportunity for the emerging product". The patient population covered by the endpoint represents the largest commercial opportunity for zanzalintinib, analysts said, estimating peak risk-adjusted sales in the US at $875 million.


https://www.fiercebiotech.com/biotech/exelixis-blockbuster-hopeful-beats-bayer-drug-pivotal-cancer-trial-sending-stock-25

attachment
5
28 ComentĂĄrios

imagem de perfil
I just didn't understand anything.😂 Hold or sell?✅😅
••
imagem de perfil
•
1
•
imagem de perfil
what do you think of the rating, my friend?
••
imagem de perfil
•
1
•
imagem de perfil
@Memo0606

I also think $CAMX is very good. Great growth
•
1
•
imagem de perfil
@Tenbagger2024 thanks
$IVN take a look at this
••
imagem de perfil
@Tenbagger2024 find $EXEL more interesting
••
imagem de perfil
@Memo0606
I consider both interesting $EXEL to be less risky.
$CAMX has very good growth and should therefore actually perform better.
•
1
•
imagem de perfil
@Memo0606
$IVN think the figures will come in the next few days.
The multiples look really good.
But the chart has not yet found a bottom.
The question is how commodities will develop if the Chinese lift the sanctions again. It's really difficult for me to judge.
•
1
•
imagem de perfil
@Tenbagger2024 but riskier
••
imagem de perfil
@Memo0606
$CAMX
The company expects fantastic profit growth of over 100% next year with an expected P/E ratio of 22.70.
The EbiT margin will rise from 36% to 46%.
These are really good figures
••
imagem de perfil
•
1
•
imagem de perfil
@Memo0606
Hope something happens soon at $KRYS
••
Ver todas as 15 restantes respostas
Participar na conversa